Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review)
Medicine International · 17.08.2023 · 3 (5)
DOI: 10.3892/mi.2023.102 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicine International, online erschienen am 17.08.2023. Verfasst von Sara Fathallah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Program, School of Science and Engineering, American University in Cairo, New Cairo 11835, Egypt. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biotechnology Program, School of Science and Engineering, American University in Cairo, New Cairo 11835, Egypt.
- Biology Department, School of Science and Engineering, American University in Cairo, New Cairo 11835, Egypt.
- Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN 46556, USA.
Zitieren
APA
Fathallah, S., Abdellatif, A., & Saadeldin, M. K. (2023). Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review). Medicine International, 3(5). https://doi.org/10.3892/mi.2023.102
Vancouver
Fathallah S, Abdellatif A, Saadeldin MK. Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review). Medicine International. 2023;3(5). doi:10.3892/mi.2023.102
BibTeX
@article{Fathallah2023,
author = {Fathallah, Sara and Abdellatif, Ahmed and Saadeldin, Mona Kamal},
title = {Unleashing nature's potential and limitations: Exploring molecular targeted pathways and safe alternatives for the treatment of multiple sclerosis (Review)},
journal = {Medicine International},
year = {2023},
volume = {3},
number = {5},
doi = {10.3892/mi.2023.102}
}
EUVIMED